Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 31, Number 12—December 2025

Research Letter

Macrolide-Resistant Mycoplasma pneumoniae in Children, Ohio, USA

Huanyu WangComments to Author , Tori Embry, Kathy Everhart, Morgan Szekely, Jeanette Taveras, Sophonie J. Oyeniran, and Amy L. Leber
Author affiliation: Nationwide Children’s Hospital, Columbus, Ohio, USA (H. Wang, T. Embry, K. Everhart, M. Szekely, J. Taveras, S.J. Oyeniran, A.L. Leber); The Ohio State University, Columbus (H. Wang, J. Taveras, S.J. Oyeniran, A.L. Leber)

Main Article

Figure

Monthly azithromycin prescriptions per 1,000 patients at Nationwide Children’s Hospital urgent care centers, Mycoplasma pneumoniae positive rates, and MRMp rates, Ohio, USA, September 2023–May 2025. Macrolide resistance was determined in a subset of samples. MRMp rates were not available during September 2023–December 2023. MRMp, macrolide-resistant M. pneumoniae.

Figure. Monthly azithromycin prescriptions per 1,000 patients at Nationwide Children’s Hospital urgent care centers, Mycoplasma pneumoniae positive rates, and MRMp rates, Ohio, USA, September 2023–May 2025. Macrolide resistance was determined in a subset of samples. MRMp rates were not available during September 2023–December 2023. MRMp, macrolide-resistant M. pneumoniae.

Main Article

Page created: December 11, 2025
Page updated: January 01, 2026
Page reviewed: January 01, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external